Mathew Maurer Receives Distinguished Clinical Research Achievement Award from Clinical Research Forum
2019 Top Ten Clinical Research Achievement Awardee
The Irving Institute congratulates Mathew S. Maurer, MD on receiving a 2019 Top Ten Clinical Research Achievement Award from the Clinical Research Forum. Dr. Maurer’s study, “Transthyretin Cardiac Amyloidosis: Overlooked, Under Appreciated and Treatable” received the additional honor of Distinguished Clinical Research Achievement Award, presented to the top two studies that show creativity, innovation, or a novel approach that demonstrates an immediate impact on the health and well-being of patients. Each study received a $5,000 cash prize.
Transthyretin amyloid cardiomyopathy is an under-diagnosed and often overlooked cause of heart failure. Dr. Maurer’s randomized, double blind, prospective, and international multicenter study evaluated the drug tafamidis for patients with the genetic and non-genetic forms of transthyretin amyloidosis. Use of the drug showed a significant reduction in mortality and frequency of cardiovascular-related hospitalizations. Collectively, these findings indicate that tafamidis is the first effective therapy for patients with transthyretin amyloid cardiomyopathy.
Read more about Dr. Maurer’s research story.